Abstract:The urokinase system is involved in a variety of physiological processes, such as fibrinolysis, matrix remodeling, wound healing, and regeneration. Upon binding to its cognate receptor urokinase-type plasminogen activator receptor (uPAR), urokinase-type plasminogen activator (uPA) catalyzes the conversion of plasminogen to plasmin and the activation of matrix metalloproteases. Apart from this, uPA-uPAR interaction can lead to the activation of transcription factors, mitogenactivated protein kinase signaling pa… Show more
“…Altogether, most reports show an active role for uPAR in EMT, even though a recent report shows that, instead, uPAR expression is essential for maintaining the epithelial phenotype in neuroblastoma Neuro2a cells, since uPAR silencing induces the down-regulation of epithelial markers (E-cadherin, occludin, and claudin-5) and the increase of mesenchymal markers (N-cadherin, α-smooth muscle actin, and interleukin-6) [ 70 ].…”
Proteolysis is a key event in several biological processes; proteolysis must be tightly controlled because its improper activation leads to dramatic consequences. Deregulation of proteolytic activity characterizes many pathological conditions, including cancer. The plasminogen activation (PA) system plays a key role in cancer; it includes the serine-protease urokinase-type plasminogen activator (uPA). uPA binds to a specific cellular receptor (uPAR), which concentrates proteolytic activity at the cell surface, thus supporting cell migration. However, a large body of evidence clearly showed uPAR involvement in the biology of cancer cell independently of the proteolytic activity of its ligand. In this review we will first describe this multifunctional molecule and then we will discuss how uPAR can sustain most of cancer hallmarks, which represent the biological capabilities acquired during the multistep cancer development. Finally, we will illustrate the main data available in the literature on uPAR as a cancer biomarker and a molecular target in anti-cancer therapy.
“…Altogether, most reports show an active role for uPAR in EMT, even though a recent report shows that, instead, uPAR expression is essential for maintaining the epithelial phenotype in neuroblastoma Neuro2a cells, since uPAR silencing induces the down-regulation of epithelial markers (E-cadherin, occludin, and claudin-5) and the increase of mesenchymal markers (N-cadherin, α-smooth muscle actin, and interleukin-6) [ 70 ].…”
Proteolysis is a key event in several biological processes; proteolysis must be tightly controlled because its improper activation leads to dramatic consequences. Deregulation of proteolytic activity characterizes many pathological conditions, including cancer. The plasminogen activation (PA) system plays a key role in cancer; it includes the serine-protease urokinase-type plasminogen activator (uPA). uPA binds to a specific cellular receptor (uPAR), which concentrates proteolytic activity at the cell surface, thus supporting cell migration. However, a large body of evidence clearly showed uPAR involvement in the biology of cancer cell independently of the proteolytic activity of its ligand. In this review we will first describe this multifunctional molecule and then we will discuss how uPAR can sustain most of cancer hallmarks, which represent the biological capabilities acquired during the multistep cancer development. Finally, we will illustrate the main data available in the literature on uPAR as a cancer biomarker and a molecular target in anti-cancer therapy.
“…Since uPAR lacks transmembrane or intracellular domains, it needs to interact with transmembrane receptors and complexes to trigger downstream signaling and promote tumor cell proliferation 4 . Recently, Wang K et al 59 and Semina EV et al 64 knocked out uPAR with the CRISPR/Cas9 system, successfully resulting in suppression of human cancer cell proliferation. Silencing uPAR can inhibit the expression of the MMP2, MMP9 and P-ERK proteins in oral and tongue squamous cell carcinoma and attenuate cell proliferation 65 .…”
Tumorigenesis is closely related to the loss of control of many genes. Urokinase-type plasminogen activator receptor (uPAR), a glycolipid-anchored protein on the cell surface, is controlled by many factors in tumorigenesis and is expressed in many tumor tissues. In this review, we summarize the regulatory effects of the uPAR signaling pathway on processes and factors related to tumor progression, such as tumor cell proliferation, adhesion, metastasis, glycolysis, tumor microenvironment and angiogenesis. Overall, the evidence accumulated to date suggests that uPAR induction by tumor progression may be one of the most important factors affecting therapeutic efficacy. An improved understanding of the interactions between uPAR and its coreceptors in cancer will provide critical biomolecular information that may help to better predict the disease course and response to therapy.
“…Накопленные данные о роли uPA и uPAR в сосудах говорят о том, что функции урокиназной системы выходят за пределы фибринолиза, и в тканях активная урокиназа и ее рецептор оказывают ряд эффектов, направленных на их регенерацию и восстановление, однако длительное присутствие uPA в системе или чрезмерная активация uPAR могут иметь ряд противоположных эффектов. Опубликованные данные [20] свидетельствуют в пользу предположения о том, что uPAR является ловушкой урокиназы на мембране, препятствуя ее транслокации в ядро и активации транскрипционного фактора NF-kB, регулирующего эпителиально-мезенхимальный переход, как одного из маркеров фиброза. Кроме того, uPAR может регулировать продукцию клетками IL-6, а переходя в растворимую форму за счет частичного протеолиза, uPAR может функционировать как хемоаттрактант для клеток иммунной системы, связываясь с хемокиновым рецептором пептида fMLP (N-формилметионил-лейцил-фенилаланина) [21].…”
Section: роль протеаз и системы активаторов плазминогена в патогенезе коронавирусной инфекцииunclassified
The coronavirus disease 2019 (COVID-19) pandemic requires not only the creation of vaccines to prevent the spread of the disease, but also the development of novel drugs aimed at reducing viral load, suppressing an excessive immune response and preventing the severe complications such as lung fibrosis and acute respiratory distress syndrome. One of the promising targets for studying the development of pneumonia, systemic inflammation and disseminated intravascular coagulation in COVID-19 is the plasminogen activator system. In patients with a severe disease course, impaired activity or expression of plasminogen activators significantly increases the blood level of D-dimer and fibrinogen, as well as correlates with intravascular coagulation and thrombus formation. The second promising target for studying the pathogenesis of COVID-19 is the adiponectin/T-cadherin system: adiponectin is able to reduce the content of pro-inflammatory cytokines, the increase of which is characteristic of COVID-19, and stimulate the production of an anti-inflammatory cytokine interleukin-10. The review describes the role of plasminogen and T-cadherin activators in their possible participation in the development of pulmonary fibrosis in COVID-19 and hemostasis regulation, as well as cardio- and vasculoprotective function of adiponectin and its receptor, T-cadherin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.